Satoru Inoue1, Soniya Vaidya2, Hanns-Christian Tillmann3, Yohei Sakita4, Surendra Machineni5, Olivier Heudi3, Kenichi Furihata6. 1. Novartis Pharma KK, Tokyo, Japan. satoru-1.inoue@novartis.com. 2. Novartis Institutes for BioMedical Research, Cambridge, USA. 3. Novartis Institutes for BioMedical Research, Basel, Switzerland. 4. Novartis Pharma KK, Tokyo, Japan. 5. Novartis Healthcare Pvt. Ltd., Hyderabad, India. 6. P-One Clinic, Keikokai Medical Corporation, Tokyo, Japan.
Abstract
BACKGROUND: A once-daily (o.d.) fixed-dose combination of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF) delivered via the Breezhaler® device (IND/GLY/MF) is being developed for treatment of asthma. This study compared steady-state pharmacokinetics of IND, GLY and MF between Japanese and Caucasian male subjects after multiple inhalations of IND/GLY/MF o.d. METHODS: This was a single-center, open-label, 2-treatment crossover study with a 21-day washout period. Japanese and Caucasian subjects receivedIND/GLY/MF 150/50/80μg (inhaled corticosteroid [ICS] medium-dose) or 150/50/160 μg o.d. (ICS high-dose) for 14 days in each period. Pharmacokinetics were characterized up to 24 h post-dose on Days 1 and 14. RESULTS:In total, 16 Japanese (median age 31 years [range 20-40 years], mean weight 68.3 kg) and17 Caucasian subjects (median age 27 years [range 21-43 years], mean weight 75.0 kg) were randomized. Geometric mean ratios (Japanese/Caucasian) [90% confidence interval (CI)] for Cmax for IND, GLY and MF at the high ICS dose on Day 14 were 1.31 [1.13, 1.51] 1.38 [1.13, 1.69] and 1.07 [0.969, 1.18], respectively. Geometric mean ratios (Japanese/Caucasian) [90% CI] for AUC0-24h on Day 14 for IND, GLY and MF at the high ICS dose were 1.17 [1.01, 1.35], 1.05 [0.920, 1.20] and 1.15 [1.05, 1.27] respectively. Similar trends were noted for all components for the medium ICS dose treatment. IND/GLY/MF was safe and well tolerated; no AEs suspected to be study drug-related were observed. CONCLUSION:Pharmacokinetics of IND, GLY and MF (high and medium dose) when delivered as a fixed-dose combination were comparable between Japanese and Caucasian subjects. The IND/GLY/MF combination at the administrated doses was safe and well tolerated in both ethnic groups. TRIAL REGISTRATION: Japan Registry of Clinical Trial: jRCT2031200227, retrospectively registered on 04, December, 2020.
RCT Entities:
BACKGROUND: A once-daily (o.d.) fixed-dose combination of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF) delivered via the Breezhaler® device (IND/GLY/MF) is being developed for treatment of asthma. This study compared steady-state pharmacokinetics of IND, GLY and MF between Japanese and Caucasian male subjects after multiple inhalations of IND/GLY/MF o.d. METHODS: This was a single-center, open-label, 2-treatment crossover study with a 21-day washout period. Japanese and Caucasian subjects received IND/GLY/MF 150/50/80 μg (inhaled corticosteroid [ICS] medium-dose) or 150/50/160 μg o.d. (ICS high-dose) for 14 days in each period. Pharmacokinetics were characterized up to 24 h post-dose on Days 1 and 14. RESULTS: In total, 16 Japanese (median age 31 years [range 20-40 years], mean weight 68.3 kg) and 17 Caucasian subjects (median age 27 years [range 21-43 years], mean weight 75.0 kg) were randomized. Geometric mean ratios (Japanese/Caucasian) [90% confidence interval (CI)] for Cmax for IND, GLY and MF at the high ICS dose on Day 14 were 1.31 [1.13, 1.51] 1.38 [1.13, 1.69] and 1.07 [0.969, 1.18], respectively. Geometric mean ratios (Japanese/Caucasian) [90% CI] for AUC0-24h on Day 14 for IND, GLY and MF at the high ICS dose were 1.17 [1.01, 1.35], 1.05 [0.920, 1.20] and 1.15 [1.05, 1.27] respectively. Similar trends were noted for all components for the medium ICS dose treatment. IND/GLY/MF was safe and well tolerated; no AEs suspected to be study drug-related were observed. CONCLUSION: Pharmacokinetics of IND, GLY and MF (high and medium dose) when delivered as a fixed-dose combination were comparable between Japanese and Caucasian subjects. The IND/GLY/MF combination at the administrated doses was safe and well tolerated in both ethnic groups. TRIAL REGISTRATION: Japan Registry of Clinical Trial: jRCT2031200227, retrospectively registered on 04, December, 2020.
Authors: Motokazu Kato; Hironi Makita; Koji Uemura; Yoshinosuke Fukuchi; Motoi Hosoe; Charlotte Emery; Mark Higgins; Benjamin Kramer Journal: Allergol Int Date: 2010-06-25 Impact factor: 5.836
Authors: S P Myrand; K Sekiguchi; M Z Man; X Lin; R-Y Tzeng; C-H Teng; B Hee; M Garrett; H Kikkawa; C-Y Lin; S M Eddy; J Dostalik; J Mount; J Azuma; Y Fujio; I-J Jang; S-G Shin; M R Bleavins; J A Williams; J D Paulauskis; K D Wilner Journal: Clin Pharmacol Ther Date: 2008-03-19 Impact factor: 6.875
Authors: Alexander G Chuchalin; Alla N Tsoi; Kai Richter; Norbert Krug; Ronald Dahl; P B Luursema; Ray Cameron; Weibin Bao; Mark Higgins; Ralph Woessner; Andre van As Journal: Respir Med Date: 2007-07-20 Impact factor: 3.415
Authors: C LaForce; M Alexander; R Deckelmann; L M Fabbri; Z Aisanov; R Cameron; R Owen; M Higgins Journal: Allergy Date: 2008-01 Impact factor: 13.146
Authors: Harm Maarsingh; Anouk Oldenburger; Bing Han; Annet B Zuidhof; Carolina R S Elzinga; Wim Timens; Herman Meurs; Ramadan B Sopi; Martina Schmidt Journal: Cells Date: 2021-05-18 Impact factor: 6.600